BeiGene, Ltd. (6160.HK)
- Previous Close
101.900 - Open
102.600 - Bid 103.100 x --
- Ask 103.600 x --
- Day's Range
102.000 - 104.800 - 52 Week Range
75.450 - 146.500 - Volume
1,644,797 - Avg. Volume
1,424,419 - Market Cap (intraday)
145.455B - Beta (5Y Monthly) 0.63
- PE Ratio (TTM)
-- - EPS (TTM)
-4.530 - Earnings Date Jul 31, 2024 - Aug 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
170.30
BeiGene Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.
www.beigene.comRecent News: 6160.HK
Performance Overview: 6160.HK
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6160.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6160.HK
Valuation Measures
Market Cap
145.47B
Enterprise Value
131.96B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.52
Price/Book (mrq)
5.37
Enterprise Value/Revenue
6.12
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-28.39%
Return on Assets (ttm)
-11.81%
Return on Equity (ttm)
-20.87%
Revenue (ttm)
2.76B
Net Income Avi to Common (ttm)
-784.43M
Diluted EPS (ttm)
-4.530
Balance Sheet and Cash Flow
Total Cash (mrq)
2.79B
Total Debt/Equity (mrq)
31.64%
Levered Free Cash Flow (ttm)
-1.07B
Research Analysis: 6160.HK
Company Insights: 6160.HK
6160.HK does not have Company Insights